Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells

Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Molecular cancer therapeutics 2013-03, Vol.12 (3), p.314-325
Hauptverfasser: Hasei, Joe, Sasaki, Tsuyoshi, Tazawa, Hiroshi, Osaki, Shuhei, Yamakawa, Yasuaki, Kunisada, Toshiyuki, Yoshida, Aki, Hashimoto, Yuuri, Onishi, Teppei, Uno, Futoshi, Kagawa, Shunsuke, Urata, Yasuo, Ozaki, Toshifumi, Fujiwara, Toshiyoshi
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page 325
container_issue 3
container_start_page 314
container_title Molecular cancer therapeutics
container_volume 12
creator Hasei, Joe
Sasaki, Tsuyoshi
Tazawa, Hiroshi
Osaki, Shuhei
Yamakawa, Yasuaki
Kunisada, Toshiyuki
Yoshida, Aki
Hashimoto, Yuuri
Onishi, Teppei
Uno, Futoshi
Kagawa, Shunsuke
Urata, Yasuo
Ozaki, Toshifumi
Fujiwara, Toshiyoshi
description Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.
doi_str_mv 10.1158/1535-7163.MCT-12-0869
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1316377993</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1316377993</sourcerecordid><originalsourceid>FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</originalsourceid><addsrcrecordid>eNo9kc1u3CAUhVGVqJmkfYRWLLNxwo_BeFlN0jbSRNlM1ugaX3dc2WYKeKp5hTx1cSbpBtDlnHvhO4R84eyGc2VuuZKqqLiWN4_rbcFFwYyuP5BVrpvCKF6evZ5PmgtyGeNvxripBf9ILoSUXNWVXpGXuxkGug_-V4BxxJY6HAbaIqQd3eflLxwj7ad2dvmuOdK9kjQFmCK41B8g9X6i_oDB-RFpwNjHBJNDmjz1k_PDMfWOQouTP_RhXlrR3TxCNsWEPsJihNeh8RM572CI-PltvyLP3--365_F5unHw_rbpnCKm1Qg06xkXadKLGWlQbSmaTlrm0bohhkuSs2c6bRyiMaB6MpWC1U5KbKrFFpeketT3_zrPzPGZMc-Li-ACf0cLZeZWFXVtcxSdZK64GMM2Nl96EcIR8uZXWKwC2K7ILY5BsuFXWLIvq9vI-YmQ_3veucu_wHnFYau</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1316377993</pqid></control><display><type>article</type><title>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</title><source>MEDLINE</source><source>American Association for Cancer Research</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Hasei, Joe ; Sasaki, Tsuyoshi ; Tazawa, Hiroshi ; Osaki, Shuhei ; Yamakawa, Yasuaki ; Kunisada, Toshiyuki ; Yoshida, Aki ; Hashimoto, Yuuri ; Onishi, Teppei ; Uno, Futoshi ; Kagawa, Shunsuke ; Urata, Yasuo ; Ozaki, Toshifumi ; Fujiwara, Toshiyoshi</creator><creatorcontrib>Hasei, Joe ; Sasaki, Tsuyoshi ; Tazawa, Hiroshi ; Osaki, Shuhei ; Yamakawa, Yasuaki ; Kunisada, Toshiyuki ; Yoshida, Aki ; Hashimoto, Yuuri ; Onishi, Teppei ; Uno, Futoshi ; Kagawa, Shunsuke ; Urata, Yasuo ; Ozaki, Toshifumi ; Fujiwara, Toshiyoshi</creatorcontrib><description>Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.</description><identifier>ISSN: 1535-7163</identifier><identifier>EISSN: 1538-8514</identifier><identifier>DOI: 10.1158/1535-7163.MCT-12-0869</identifier><identifier>PMID: 23315976</identifier><language>eng</language><publisher>United States</publisher><subject>Adenoviridae ; Apoptosis - genetics ; Bone Neoplasms - pathology ; Bone Neoplasms - therapy ; Bone Neoplasms - virology ; Cell Cycle - genetics ; Humans ; Oncolytic Virotherapy ; Oncolytic Viruses - genetics ; Osteosarcoma - pathology ; Osteosarcoma - therapy ; Osteosarcoma - virology ; Transcriptional Activation - genetics ; Tumor Suppressor Protein p53 - genetics ; Tumor Suppressor Protein p53 - metabolism ; Xenograft Model Antitumor Assays</subject><ispartof>Molecular cancer therapeutics, 2013-03, Vol.12 (3), p.314-325</ispartof><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</citedby><cites>FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,3343,27901,27902</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/23315976$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hasei, Joe</creatorcontrib><creatorcontrib>Sasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Tazawa, Hiroshi</creatorcontrib><creatorcontrib>Osaki, Shuhei</creatorcontrib><creatorcontrib>Yamakawa, Yasuaki</creatorcontrib><creatorcontrib>Kunisada, Toshiyuki</creatorcontrib><creatorcontrib>Yoshida, Aki</creatorcontrib><creatorcontrib>Hashimoto, Yuuri</creatorcontrib><creatorcontrib>Onishi, Teppei</creatorcontrib><creatorcontrib>Uno, Futoshi</creatorcontrib><creatorcontrib>Kagawa, Shunsuke</creatorcontrib><creatorcontrib>Urata, Yasuo</creatorcontrib><creatorcontrib>Ozaki, Toshifumi</creatorcontrib><creatorcontrib>Fujiwara, Toshiyoshi</creatorcontrib><title>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</title><title>Molecular cancer therapeutics</title><addtitle>Mol Cancer Ther</addtitle><description>Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.</description><subject>Adenoviridae</subject><subject>Apoptosis - genetics</subject><subject>Bone Neoplasms - pathology</subject><subject>Bone Neoplasms - therapy</subject><subject>Bone Neoplasms - virology</subject><subject>Cell Cycle - genetics</subject><subject>Humans</subject><subject>Oncolytic Virotherapy</subject><subject>Oncolytic Viruses - genetics</subject><subject>Osteosarcoma - pathology</subject><subject>Osteosarcoma - therapy</subject><subject>Osteosarcoma - virology</subject><subject>Transcriptional Activation - genetics</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumor Suppressor Protein p53 - metabolism</subject><subject>Xenograft Model Antitumor Assays</subject><issn>1535-7163</issn><issn>1538-8514</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2013</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNo9kc1u3CAUhVGVqJmkfYRWLLNxwo_BeFlN0jbSRNlM1ugaX3dc2WYKeKp5hTx1cSbpBtDlnHvhO4R84eyGc2VuuZKqqLiWN4_rbcFFwYyuP5BVrpvCKF6evZ5PmgtyGeNvxripBf9ILoSUXNWVXpGXuxkGug_-V4BxxJY6HAbaIqQd3eflLxwj7ad2dvmuOdK9kjQFmCK41B8g9X6i_oDB-RFpwNjHBJNDmjz1k_PDMfWOQouTP_RhXlrR3TxCNsWEPsJihNeh8RM572CI-PltvyLP3--365_F5unHw_rbpnCKm1Qg06xkXadKLGWlQbSmaTlrm0bohhkuSs2c6bRyiMaB6MpWC1U5KbKrFFpeketT3_zrPzPGZMc-Li-ACf0cLZeZWFXVtcxSdZK64GMM2Nl96EcIR8uZXWKwC2K7ILY5BsuFXWLIvq9vI-YmQ_3veucu_wHnFYau</recordid><startdate>201303</startdate><enddate>201303</enddate><creator>Hasei, Joe</creator><creator>Sasaki, Tsuyoshi</creator><creator>Tazawa, Hiroshi</creator><creator>Osaki, Shuhei</creator><creator>Yamakawa, Yasuaki</creator><creator>Kunisada, Toshiyuki</creator><creator>Yoshida, Aki</creator><creator>Hashimoto, Yuuri</creator><creator>Onishi, Teppei</creator><creator>Uno, Futoshi</creator><creator>Kagawa, Shunsuke</creator><creator>Urata, Yasuo</creator><creator>Ozaki, Toshifumi</creator><creator>Fujiwara, Toshiyoshi</creator><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>201303</creationdate><title>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</title><author>Hasei, Joe ; Sasaki, Tsuyoshi ; Tazawa, Hiroshi ; Osaki, Shuhei ; Yamakawa, Yasuaki ; Kunisada, Toshiyuki ; Yoshida, Aki ; Hashimoto, Yuuri ; Onishi, Teppei ; Uno, Futoshi ; Kagawa, Shunsuke ; Urata, Yasuo ; Ozaki, Toshifumi ; Fujiwara, Toshiyoshi</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c518t-e06040ff54e4376a2d8bd10dbb26b0812460c8f65cee8ca2f4d6257c3240f4263</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2013</creationdate><topic>Adenoviridae</topic><topic>Apoptosis - genetics</topic><topic>Bone Neoplasms - pathology</topic><topic>Bone Neoplasms - therapy</topic><topic>Bone Neoplasms - virology</topic><topic>Cell Cycle - genetics</topic><topic>Humans</topic><topic>Oncolytic Virotherapy</topic><topic>Oncolytic Viruses - genetics</topic><topic>Osteosarcoma - pathology</topic><topic>Osteosarcoma - therapy</topic><topic>Osteosarcoma - virology</topic><topic>Transcriptional Activation - genetics</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumor Suppressor Protein p53 - metabolism</topic><topic>Xenograft Model Antitumor Assays</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hasei, Joe</creatorcontrib><creatorcontrib>Sasaki, Tsuyoshi</creatorcontrib><creatorcontrib>Tazawa, Hiroshi</creatorcontrib><creatorcontrib>Osaki, Shuhei</creatorcontrib><creatorcontrib>Yamakawa, Yasuaki</creatorcontrib><creatorcontrib>Kunisada, Toshiyuki</creatorcontrib><creatorcontrib>Yoshida, Aki</creatorcontrib><creatorcontrib>Hashimoto, Yuuri</creatorcontrib><creatorcontrib>Onishi, Teppei</creatorcontrib><creatorcontrib>Uno, Futoshi</creatorcontrib><creatorcontrib>Kagawa, Shunsuke</creatorcontrib><creatorcontrib>Urata, Yasuo</creatorcontrib><creatorcontrib>Ozaki, Toshifumi</creatorcontrib><creatorcontrib>Fujiwara, Toshiyoshi</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Molecular cancer therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hasei, Joe</au><au>Sasaki, Tsuyoshi</au><au>Tazawa, Hiroshi</au><au>Osaki, Shuhei</au><au>Yamakawa, Yasuaki</au><au>Kunisada, Toshiyuki</au><au>Yoshida, Aki</au><au>Hashimoto, Yuuri</au><au>Onishi, Teppei</au><au>Uno, Futoshi</au><au>Kagawa, Shunsuke</au><au>Urata, Yasuo</au><au>Ozaki, Toshifumi</au><au>Fujiwara, Toshiyoshi</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells</atitle><jtitle>Molecular cancer therapeutics</jtitle><addtitle>Mol Cancer Ther</addtitle><date>2013-03</date><risdate>2013</risdate><volume>12</volume><issue>3</issue><spage>314</spage><epage>325</epage><pages>314-325</pages><issn>1535-7163</issn><eissn>1538-8514</eissn><abstract>Tumor suppressor p53 is a multifunctional transcription factor that regulates diverse cell fates, including apoptosis and autophagy in tumor biology. p53 overexpression enhances the antitumor activity of oncolytic adenoviruses; however, the molecular mechanism of this occurrence remains unclear. We previously developed a tumor-specific replication-competent oncolytic adenovirus, OBP-301, that kills human osteosarcoma cells, but some human osteosarcoma cells were OBP-301-resistant. In this study, we investigated the antitumor activity of a p53-expressing oncolytic adenovirus, OBP-702, and the molecular mechanism of the p53-mediated cell death pathway in OBP-301-resistant human osteosarcoma cells. The cytopathic activity of OBP-702 was examined in OBP-301-sensitive (U2OS and HOS) and OBP-301-resistant (SaOS-2 and MNNG/HOS) human osteosarcoma cells. The molecular mechanism in the OBP-702-mediated induction of two cell death pathways, apoptosis and autophagy, was investigated in OBP-301-resistant osteosarcoma cells. The antitumor effect of OBP-702 was further assessed using an orthotopic OBP-301-resistant MNNG/HOS osteosarcoma xenograft tumor model. OBP-702 suppressed the viability of OBP-301-sensitive and -resistant osteosarcoma cells more efficiently than OBP-301 or a replication-deficient p53-expressing adenovirus (Ad-p53). OBP-702 induced more profound apoptosis and autophagy when compared with OBP-301 or Ad-p53. E1A-mediated miR-93/106b upregulation induced p21 suppression, leading to p53-mediated apoptosis and autophagy in OBP-702-infected cells. p53 overexpression enhanced adenovirus-mediated autophagy through activation of damage-regulated autophagy modulator (DRAM). Moreover, OBP-702 suppressed tumor growth in an orthotopic OBP-301-resistant MNNG/HOS xenograft tumor model. These results suggest that OBP-702-mediated p53 transactivation is a promising antitumor strategy to induce dual apoptotic and autophagic cell death pathways via regulation of miRNA and DRAM in human osteosarcoma cells.</abstract><cop>United States</cop><pmid>23315976</pmid><doi>10.1158/1535-7163.MCT-12-0869</doi><tpages>12</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 1535-7163
ispartof Molecular cancer therapeutics, 2013-03, Vol.12 (3), p.314-325
issn 1535-7163
1538-8514
language eng
recordid cdi_proquest_miscellaneous_1316377993
source MEDLINE; American Association for Cancer Research; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals
subjects Adenoviridae
Apoptosis - genetics
Bone Neoplasms - pathology
Bone Neoplasms - therapy
Bone Neoplasms - virology
Cell Cycle - genetics
Humans
Oncolytic Virotherapy
Oncolytic Viruses - genetics
Osteosarcoma - pathology
Osteosarcoma - therapy
Osteosarcoma - virology
Transcriptional Activation - genetics
Tumor Suppressor Protein p53 - genetics
Tumor Suppressor Protein p53 - metabolism
Xenograft Model Antitumor Assays
title Dual programmed cell death pathways induced by p53 transactivation overcome resistance to oncolytic adenovirus in human osteosarcoma cells
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-31T05%3A11%3A40IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Dual%20programmed%20cell%20death%20pathways%20induced%20by%20p53%20transactivation%20overcome%20resistance%20to%20oncolytic%20adenovirus%20in%20human%20osteosarcoma%20cells&rft.jtitle=Molecular%20cancer%20therapeutics&rft.au=Hasei,%20Joe&rft.date=2013-03&rft.volume=12&rft.issue=3&rft.spage=314&rft.epage=325&rft.pages=314-325&rft.issn=1535-7163&rft.eissn=1538-8514&rft_id=info:doi/10.1158/1535-7163.MCT-12-0869&rft_dat=%3Cproquest_cross%3E1316377993%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1316377993&rft_id=info:pmid/23315976&rfr_iscdi=true